Neurodegenerative Diseases Related Content

The vital work of the National Institute on Deafness and Other Communication Disorders (NIDCD) and The National Institute of Neurological Disorders and Stroke (NINDS) are explored here by Open Access Government, with a special focus on neurodegenerative disorders.

Tamas Fulop from Université de Sherbrooke’s Research Center on Aging, explains precisely why infections may be the new paradigm explaining the pathogenesis of Alzheimer’s disease (AD)

The DZNE investigates the causes of neurodegenerative diseases and develops novel strategies for prevention, treatment and care.

NIH-funded study closes in on personalised drug testing for neurological disorders

Scientists from the National Institutes of Health (NIH) compared the genetic clocks of normal and mutant flies to understand the link between neurodegenerative disorders such as Alzheimer’s disease and the ageing process

Svein Olaf Olsen and Maiken Arnesen from the European Huntington Association reveal their thoughts on a recent and significant breakthrough concerning Huntington’s Disease (HD) research The 11th December 2017 will probably go into history along with the discovery of the Huntington gene in 1993. On this date, IONIS Pharmaceuticals announced...

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

The European Parkinson’s Disease Association (EPDA) provide an update about the positive progress being made for people with Parkinson’s My PD Journey is a multi-stakeholder European coalition led by the European Parkinson’s Disease Association (EPDA) and it is a positive development in terms of the positive progress being made for...

The defect that causes Huntington's disease has been corrected in patients for the first time with an experimental drug Experts believe that the new experimental drug, which is injected into spinal fluid, could be the biggest breakthrough in neurodegenerative diseases for 50 years. The unstoppable death of brain cells in Huntington's gradually causes...

Prof. Dr Axel Rominger from the Ludwig-Maximilian-University of Munich on how neurodegenerative diseases can be studied through PET imaging

Prof. David Dexter, deputy director of research at Parkinson’s UK shares his thoughts on the symptoms of Parkinson’s and the chances of finding a cure

The Alzheimer's Society in the UK provides a fascinating glimpse into the most dementia as a progressive condition and its common forms

Naoko Tanese from New York University explores how monitoring gene expression can be used to treat neurodegenerative diseases such as Huntington's

A man in a vegetative state in France has regained a degree of consciousness after experimental therapy of placing a nerve stimulator on his chest After being in a vegetative state for 15 years, the unnamed 35-year-old patient responded to nerve stimulator therapy and within a month was able to...

Writing on behalf of the Chartered Society of Physiotherapy, Dr. Bhanu Ramaswamy highlights how physiotherapy can help manage the symptoms of Parkinson’s

Frederic Destrebecq, Vinciane Quoidbach and Alison Turner at the European Brain Council discuss improvements in stroke care, awareness raising and early detection Stroke is a leading cause of disability and mortality among adults. It is the third cause of death worldwide and the first cause of acquired disability.1 Despite improvements...

Dr Mehis Pilv, CEO and business development lead at Genecode, discusses the strides being made in Parkinson's disease research Parkinson's disease is a slow but progressive neurodegenerative disorder. About 1% of people aged above 50 are affected worldwide. In Europe alone 1.2 million people suffer from Parkinson's disease, 127,000 of whom...

The changing pharma landscape means opportunities for Parkinson's drug discovery are missed, but Parkinson's UK have a new strategy to redress the balance This will be the 200th year since James Parkinson wrote his seminal paper on ‘the Shaking Palsy’. Since that time there have been major developments in the...

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...